Emerging Growth Patterns, Market Segmentation, and Competitive Approaches Influencing the Future of the Antibody Therapeutics Market

The next-generation antibody therapeutics market is on the verge of significant expansion as innovative technologies and increasing health challenges drive demand. With advancements in antibody engineering and a growing focus on personalized medicine, this sector is set to transform treatment options across various diseases. Let's delve into the market's size, key players, prominent trends, and the segmentation landscape shaping its future.

Projected Market Size and Growth Trajectory of the Next-Generation Antibody Therapeutics Market
The market for next-generation antibody therapeutics is expected to experience swift growth, reaching a valuation of $12.63 billion by 2030. This expansion corresponds to a compound annual growth rate (CAGR) of 10.9%. Factors fueling this growth include progress in antibody engineering techniques, heightened demand for targeted therapies, rising rates of chronic and autoimmune conditions, increasing clinical trial activities in emerging regions, and robust collaborations between biotechnology firms and pharmaceutical companies. Key trends anticipated throughout the forecast period involve the expansion of bispecific and multispecific antibody platforms, broader adoption of antibody-drug conjugates particularly in oncology, focus on developing high-affinity and long-lasting antibodies, growth of clinical pipelines targeting rare and orphan diseases, and a shift towards personalized antibody-based treatments.

Download a free report of the next-generation antibody therapeutics market report:
https://www.thebusinessresearchcompany.com/report/next-generation-antibody-therapeutics-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Important Contributors in the Next-Generation Antibody Therapeutics Market
Several leading companies are shaping the next-generation antibody therapeutics landscape. These include Pfizer Inc., F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Amgen Inc., Regeneron Pharmaceuticals Inc., Biogen Inc., Genentech Inc., Kyowa Hakko Kirin Co. Ltd., Seagen Inc., Seattle Genetics Inc., Xencor Inc., ImmunoGen Inc., Genmab A/S, Zymeworks Inc., NBE-Therapeutics AG, Daiichi Sankyo Company Limited, Merck & Co Inc., Novartis AG, AbCellera Biologics Inc., Sotio Biotech, F-Star Therapeutics Ltd., ADC Therapeutics SA, and Harbour BioMed.

Strategic Acquisition Enhancing Market Capabilities
In a significant move in February 2024, AbbVie Inc., a US pharmaceutical giant, acquired ImmunoGen, Inc. for about US$10.1 billion. This acquisition strengthens AbbVie's portfolio in next-generation antibody therapeutics by incorporating ImmunoGen's folate receptor-alpha-targeted antibody-drug conjugate, ELAHERE, which is approved for treating platinum-resistant ovarian cancer. Additionally, AbbVie aims to broaden its pipeline of antibody-drug conjugates targeting both solid tumors and hematologic cancers. ImmunoGen, Inc. is known for its specialization in innovative antibody-drug conjugate platforms within oncology.

View the full next-generation antibody therapeutics market report:
https://www.thebusinessresearchcompany.com/report/next-generation-antibody-therapeutics-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Emerging Trends Positively Impacting Next-Generation Antibody Therapeutics Growth
Developers in the technetium-99m market are prioritizing innovation by creating advanced radiopharmaceutical imaging agents that improve diagnostic accuracy for complex diseases. These agents are radioactive compounds designed to enhance the visualization of internal body structures through imaging techniques. For example, in June 2024, Serac Healthcare Limited, a UK-based radiopharmaceutical company, earned Fast Track Designation from the US Food and Drug Administration (FDA) for 99mTc-maraciclatide. This novel single-photon emission computed tomography (SPECT)-computed tomography (CT) imaging agent is intended for diagnosing superficial peritoneal endometriosis in women aged 16 and older.

Significance of Novel Imaging Agents in Diagnostic Medicine
99mTc-maraciclatide works by targeting integrins that are ere*xpressed in endometriosis lesions, enabling clear visualization of affected areas during SPECT-CT scanning. This provides a non-invasive alternative to laparoscopic diagnosis, making it a safer and more accessible option for women suspected to have endometriosis. The agent benefits from technetium-99m's favorable imaging characteristics, including an ideal half-life and gamma emission energy, which allow high-quality images while limiting radiation exposure. This breakthrough promises to enhance diagnostic precision and streamline treatment decisions for endometriosis while expanding the clinical uses of technetium-99m-based imaging in women's health care.

Detailed Segmentation of the Next-Generation Antibody Therapeutics Market
The report divides the next-generation antibody therapeutics market into various segments as follows:

By Types of Antibodies:
- Monoclonal Antibodies
- Polyclonal Antibodies
- Bispecific Antibodies
- Antibody-Drug Conjugates
- Other Types

By Therapeutic Areas:
- Oncology
- Autoimmune Diseases
- Infectious Diseases
- Neurodegenerative Disorders
- Other Therapeutic Areas

By End-Users:
- Hospitals and Clinics
- Research Institutes
- Pharmaceutical and Biotechnology Companies
- Other End-Users

Further subcategories include:
For Monoclonal Antibodies - IgG Monoclonal Antibodies, IgM Monoclonal Antibodies
For Polyclonal Antibodies - Serum-Derived Polyclonal Antibodies, Hybridoma-Derived Polyclonal Antibodies
For Bispecific Antibodies - Dual-Targeting Antibodies, Single-Chain Variable Fragment (scFv) Antibodies
For Antibody-Drug Conjugates (ADCs) - Targeted ADCs, Various Payload Types
For Other Types - Nanobodies, Engineered Antibodies

This segmentation provides a comprehensive framework to understand the diverse landscape and application areas within the next-generation antibody therapeutics market.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.